Phase 3 Clinical Trial: Brain Cancer Vaccine Shows Promising Results

Results of a phase three clinical trial of a novel brain cancer vaccine, DCVax-L, that uses a patient's stem cells to target cancer cells extend survival by many months to years for glioblastoma patients.